PMID- 32970455
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2325-6621 (Electronic)
IS  - 2325-6621 (Linking)
VI  - 18
IP  - 3
DP  - 2021 Mar
TI  - Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis 
      Questionnaire in a Multicenter Prospective Study.
PG  - 477-485
LID - 10.1513/AnnalsATS.202006-607OC [doi]
AB  - Rationale: Improvement of quality of life (QoL) in patients with sarcoidosis is 
      an important goal of management. The King's Sarcoidosis Questionnaire (KSQ) and 
      Patient Global Assessment (PGA) are instruments that have been used in 
      sarcoidosis.Objectives: We defined the minimal clinically important difference 
      (MCID) as the within-patient clinically meaningful change threshold and 
      determined the MCID of KSQ general health (KSQ GH), KSQ lung, and PGA using both 
      anchor and distribution methods. The discriminatory properties of these MCIDs 
      relative to other QoL instruments were then determined.Methods: Patients with 
      sarcoidosis recruited from six centers in the United States were prospectively 
      studied. Initially and at 6 months, patients completed a series of QoL 
      questionnaires, including the St. George's Respiratory Questionnaire (SGRQ), 
      Short Form 36 (SF-36), Fatigue Assessment Scale (FAS), Sarcoidosis Assessment 
      Tool (SAT), KSQ, and PGA, and spirometry. For the anchor method, receiver 
      operator characteristic curves were used to determine the MCID for improvement or 
      worsening. The distribution method using half of the standard deviation was 
      calculated for KSQ GH, KSQ lung, and PGA.Results: Of the 325 patients enrolled in 
      the study, 271 completed the 6-month evaluation. At 6 months, approximately half 
      of patients were worse and 30% were improved based on previously established MCID 
      values for the SGRQ, SF-36, and FAS. There were no discordant cases. There were 
      significant correlations between the KSQ GH, KSQ lung, and PGA and most 
      parameters assessed. The best correlations were with the SGRQ, SF-36, and FAS, 
      which have established MCID values. Using anchor analysis, we found that most of 
      the domains of SGRQ and SF-36 were able to determine the significant MCIDs for 
      all three variables. These MCIDs were similar to those determined by the half 
      least square method. We propose an MCID of 8 for the KSQ GH, an MCID of 4 for the 
      KSQ lung, and an MCID of 2 for the PGA because these values captured >90% of 
      parameters studied. These MCID values discriminated between changes in other QoL 
      instruments.Conclusions: The determination of MCID values for KSQ lung, KSQ GH, 
      and PGA may prove useful for clinical practice as well as clinical trials.
FAU - Baughman, Robert P
AU  - Baughman RP
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
FAU - Judson, Marc A
AU  - Judson MA
AD  - Albany Medical College, Albany, New York.
FAU - Beaumont, Jennifer L
AU  - Beaumont JL
AD  - Clinical Outcomes Solutions, Tucson, Arizona.
FAU - Maier, Lisa A
AU  - Maier LA
AD  - National Jewish, Denver, Colorado.
FAU - Sweiss, Nadera J
AU  - Sweiss NJ
AD  - University of Illinois, Chicago, Illinois.
FAU - Culver, Daniel A
AU  - Culver DA
AD  - Cleveland Clinic, Cleveland, Ohio.
FAU - Chen, Edward S
AU  - Chen ES
AUID- ORCID: 0000-0003-0723-8209
AD  - Johns Hopkins Medical Center, Baltimore, Maryland.
FAU - Singh, Noopur
AU  - Singh N
AD  - Foundation for Sarcoidosis Research, Chicago, Illinois.
FAU - Lower, Elyse E
AU  - Lower EE
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
FAU - Reeves, Rebecca
AU  - Reeves R
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
FAU - Hamzeh, Nabeel
AU  - Hamzeh N
AUID- ORCID: 0000-0001-7296-8975
AD  - National Jewish, Denver, Colorado.
AD  - University of Iowa, Iowa City, Iowa.
FAU - Grutters, Jan C
AU  - Grutters JC
AD  - Interstitial Lung Disease Center of Excellence, Department of Pulmonology, St. 
      Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Valeyre, Dominique
AU  - Valeyre D
AD  - Institut National de la Sante et de la Recherche Medicale 1272, Universite 
      Sorbonne Paris Nord, Assitance Publique-Hopital de Paris, Hopital Avicenne, 
      Bobigny, France; and.
FAU - Birring, Surinder S
AU  - Birring SS
AD  - Centre for Human and Applied Physiological Sciences, King's College London, 
      London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Am Thorac Soc
JT  - Annals of the American Thoracic Society
JID - 101600811
SB  - IM
CIN - Ann Am Thorac Soc. 2021 Mar;18(3):417-418. PMID: 33646080
MH  - Humans
MH  - Minimal Clinically Important Difference
MH  - Prospective Studies
MH  - *Quality of Life
MH  - *Sarcoidosis/diagnosis
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - St. George's Respiratory Questionnaire
OT  - quality of life
OT  - sarcoidosis
EDAT- 2020/09/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/24 17:13
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/24 17:13 [entrez]
AID - 10.1513/AnnalsATS.202006-607OC [doi]
PST - ppublish
SO  - Ann Am Thorac Soc. 2021 Mar;18(3):477-485. doi: 10.1513/AnnalsATS.202006-607OC.